Clinical Trial

Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:

Study acronym: BREAKER
Recruiting
View on ClinicalTrials.gov →
Summary
This is a multicenter observational study with both retrospective and prospective phase, designed to evaluate the clinico-pathologic characteristics and outcomes of patients with HR+/HER2- EBC at high risk of recurrence treated with ribociclib or abemaciclib in combination with ET in the adjuvant setting.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-09-12; most recent amendment 2026-05-28.
Status change: Not Yet Recruiting → Recruiting 2026-01-02
Trial Details
NCT Number NCT07180693
Lead Sponsor European Institute of Oncology
Conditions Adjuvant Therapy, CDK4/6 Inhibitor
Enrollment 750 participants
Start Date 2025-09-29
Primary Completion 2028-08-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-29